European Leukemia Trial Registry
Trial: ONTARGET

More Details
Title Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 MDS
Scientific Title A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Short Title ONTARGET
Trialgroup Deutsche MDS
Type of Trial single-group, open-label
Disease Myelodysplastic Syndrome(MDS) Low risk and intermedia I
Myelodysplastic Syndrome(MDS) Intermedia II and high risk
Age >= 18 years
Status Closed
Start of Recruitment 01.05.2012
Leader Platzbecker, Prof. Dr. med., Uwe
Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
created 25.04.2013 Sina Hehn
changed 28.08.2014 Johannes Kraus
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org